摘要
Idiopathic pulmonary fibrosis(IPF)is a chronic,progressive,and generally fatal fibrotic lung disease with a median survival of 2 to 3 years after diagnosis.[1,2]Acute exacerbation of IPF(AE-IPF)is defined as an acute,clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.Nearly 46%of deaths in IPF are caused by AE-IPF,and the median survival of patients with AE-IPF is approximately 3 to 4 months.[3]Over the past 27 years,great efforts have been paid to find therapies that might work for patients with this condition.We herein summarize current therapies for patients with AE-IPF.
基金
This work was supported by grants from the Chinese Academy of Medical Sciences Fund(No.2018-12M-1-001 and No.2019PT320021).